Frontlight ResearchEarly access
CompletedNo phase
Sphenopalatine Ganglion Block with Tx360 for Trigeminal Neuralgia
Key facts
- Who runs it
- Aretaieio Hospital
- Where
- Greece1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 15 people enrolled
- Started
- 28 Feb 2021
- Ended
- 15 Apr 2024
- Type of study
- Observational
- Treatments tested
- SPG block with the use of the Tx360 device
- Record updated
- 29 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- male or female
- older than 18 years
- ASA I or II
- trigeminal neuralgia of any etiology
Who cannot take part
- rhinitis or nasal inflammation due to medication,
- nasal or paranasal sinus surgery (within the last 3 months)
- nasal septum perforation,
- dryness or irritation of the nasal mucosa, localized pain, nasal discharge, or bleeding from the nose,
- disorders related to bleeding or coagulation,
- presence of malignancies, including angiofibroma or other tumors of the paranasal sinuses, or granulomas,
- anatomical abnormalities of the nasal septum,
- significant respiratory distress,
- persistent nasal congestion lasting more than 10 days, accompanied by high fever, discolored nasal mucosa, or facial pain and headaches,
- nasal or skull fractures occurring within the last 3 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study was to investigate the effect of sphenopalatine ganglion (SPG) block bilaterally through a nasal device called Tx360 by delivering 0.3cc of lidocaine 2% for pain relief in patients with Trigeminal Neuralgia (TN).
The group in the trial
- Fifteen patients of both sexes, older than 18 years, ASA I or II, TN of any etiology
Patients will undergo bilateral sphenopalatine ganglion block with Tx360 nasal applicator using 0.3cc lidocaine 2% in each side, once every week, for a 6-week period.
Treatment: SPG block with the use of the Tx360 device
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sphenopalatine Ganglion Block with Tx360 Nasal Applicator for Trigeminal Neuralgia: a Prospective Observational Study
- Record updated
- 29 October 2024